SISRAM MED (01696) experienced a sharp decline during the intraday trading session, with its stock price plummeting by 5.64%. This drop follows a significant 13% plunge in the previous trading day, indicating continued investor concern over the company's performance.

The sell-off appears to be driven by SISRAM MED's recently released interim results for 2025, which revealed disappointing financial figures. The company reported a revenue of US$165 million, representing a 1.9% year-on-year decrease. More notably, profit attributable to owners of the parent company fell by 41.3% year-on-year to US$6.426 million, significantly underperforming compared to the previous year.

According to the company's announcement, the decline in revenue was primarily attributed to challenging conditions in the North American market, including high interest rates and weak consumption. Additionally, transportation restrictions due to regional tensions in June resulted in slight delays in revenue recognition. Despite these setbacks, SISRAM MED's international markets outside North America achieved a 7.1% growth compared to the same period in 2024. Analysts from Shenwan Hongyuan maintain a positive long-term outlook for the company, citing its strong position in the energy-based aesthetic medical device sector and potential for performance recovery in the second half of the year, driven by new product launches and expansion of its combination therapy ecosystem.